ArticleThe Kaohsiung journal of medical sciences2026
Predictive Value of Nutrition Indices in Advanced Hepatocellular Carcinoma Patients Treated With Lenvatinib.
Article in The Kaohsiung journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diagnostic value of geriatric nutritional risk index and phase angle for malnutrition in patients with COPD: a retrospective cohort study.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prognostic nutritional index (PNI) and geriatric nutritional risk index (GNRI) are simple markers that reflect immune and nutritional status. This retrospective study evaluated their prognostic significance in 276 patients with advanced hepatocellular carcinoma (HCC) who received first-line lenvatinib. PNI and GNRI were calculated based on serum albumin, lymphocyte count, and body weight. Patients were classified into high and low groups for each index. Multivariate models were used to assess their prognostic value for progression-free survival (PFS) and overall survival (OS). Higher PNI (cut-off: 45) and GNRI (cut-off: 98) scores were associated with significantly better outcomes: the high PNI and low PNI groups achieved median PFS of 7.5 vs. 4.0 months (p = 0.002) and OS of 19.3 vs. 9.8 months (p < 0.001), respectively. Similarly, the high GNRI and low GNRI groups achieved median PFS of 7.3 versus 4.7 months (p = 0.001) and OS of 21 versus 9.8 months (p < 0.001), respectively. Patients with higher indices also had higher objective response rates, lower rates of severe treatment-related adverse events, and were more likely to receive posttreatment therapies. The PNI (hazard ratio [HR]: 0.678, p = 0.018), GNRI (HR: 0.679, p = 0.031), and the combined indices (HR: 0.655, p = 0.013) independently demonstrated prognostic value for mortality in multivariate models. PNI and GNRI, both individually and in combination, are simple yet powerful tools that predict survival and treatment tolerance in patients with HCC receiving lenvatinib. Routine assessment of these indices may enhance patient stratification and guide therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.